Report for Q1 2026
Filed with SSE · · 13 pages · Chinese
Shenzhen Chipscreen Biosciences Co. Ltd. on 6ix
Earlier from Shenzhen Chipscreen Biosciences
- Indicative Announcement on the Adjustment of Convertible Bond Conversion Prices and Continuous Suspension for Convertible Shares during the Implementation of 2025 Annual Dividend Distribution
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Conversion Result of Convertible Bonds and Share Changes
- Announcement on Resolutions of the 25th Meeting of the 3rd Board of Directors
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of Siglitazone Sodium and Metformin Hydrochloride Extended-Release Tablets
Later from Shenzhen Chipscreen Biosciences
- Announcement on Convening the Q1 2026 Performance Briefing
- Announcement on Adjusting the Conversion Price of "Chipscreen Convertible Bonds" Due to the Implementation of the 2025 Annual Profit Distribution and Resumption of Trading After Conversion Suspension
- Announcement on Receipt of the "Decision on the Examination of an Invalidity Declaration Request" from the China National Intellectual Property Administration
- Announcement on Voluntary Disclosure of Approval of Chiglitazar Sodium for Market Release by the Pharmaceutical Administration Bureau, Macao SAR
- Shareholders' Inquiry Transfer Plan
Follow Shenzhen Chipscreen Biosciences into a list and get an email when it puts out news.
Follow Shenzhen Chipscreen Biosciences